Trial · NCT02029495

Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis

NCT02029495, Phase 3, Terminated, Bausch Health Americas, Inc.; results first posted 2017-05-19

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis. Trials, record NCT02029495. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02029495

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis
NCT number: NCT02029495
Status: Terminated
Phases: Phase 3
Enrollment: 478 participants, actual
Lead sponsor: Bausch Health Americas, Inc.
Conditions: Psoriatic Arthritis
Interventions: 210 mg brodalumab, 140 mg brodalumab, Placebo
First posted: 2014-01-08
Last updated: 2017-05-19
Other registries' IDs: eudract:2013-003554-25
Results first posted: 2017-05-19

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	American College of Rheumatology (ACR) 20 Response	16 weeks	An ACR20 response is defined as at least 20% improvement of tender and swollen joint counts combined with at least 20% improvement in at least 3 of the following 5 parameters: Patients Global Assessment, PtGA of disease activity, patient's assessment of pain, Health Assessment Questionnaire-Disability Index (HAQ-DI), and either Erythrocycte sedimentation rate (ESR) or C-Reactive protein (CRP) (ACR components).
Secondary	Psoriasis Area and Severity Index (PASI)75	16 Weeks	PASI75 indicates that the subject has had a response of a 75% reduction on the severity of the psoriasis area based of off effected area size, erythema, scaling, and itching.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	American College of Rheumatology (ACR) 20 Response	16 weeks		percentage of participants	NUMBER
SECONDARY	Psoriasis Area and Severity Index (PASI)75	16 Weeks		percentage of participants	NUMBER

Source ClinicalTrials.gov

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
American College of Rheumatology (ACR) 20 Response	210 mg Brodalumab	0	95% Confidence Interval 0 to 0	percentage of participants
American College of Rheumatology (ACR) 20 Response	140 mg Brodalumab	21.8	95% Confidence Interval 10.6 to 33.1	percentage of participants
American College of Rheumatology (ACR) 20 Response	Placebo	36.5	95% Confidence Interval 22.8 to 45.3	percentage of participants
Psoriasis Area and Severity Index (PASI)75	210 mg Brodalumab	70.3	95% Confidence Interval 57.6 to 82.9	percentage of participants
Psoriasis Area and Severity Index (PASI)75	140 mg Brodalumab	55.6	95% Confidence Interval 27.9 to 56.6	percentage of participants
Psoriasis Area and Severity Index (PASI)75	Placebo	0	95% Confidence Interval 0 to 0	percentage of participants

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	210 mg Brodalumab	159
Overall Study	STARTED	140 mg Brodalumab	158
Overall Study	STARTED	Placebo	161
Overall Study	COMPLETED	210 mg Brodalumab	158
Overall Study	COMPLETED	140 mg Brodalumab	158
Overall Study	COMPLETED	Placebo	159
Overall Study	NOT COMPLETED	210 mg Brodalumab	1
Overall Study	NOT COMPLETED	140 mg Brodalumab	0
Overall Study	NOT COMPLETED	Placebo	2

Source ClinicalTrials.gov

Adverse events147

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Nasopharyngitis	Infections and infestations	210 mg Brodalumab	24	158
other	Nasopharyngitis	Infections and infestations	140 mg Brodalumab	28	158
other	Nasopharyngitis	Infections and infestations	Placebo	7	159
other	Upper Respiratory tract Infection	Infections and infestations	210 mg Brodalumab	9	158
other	Upper Respiratory tract Infection	Infections and infestations	140 mg Brodalumab	9	158
other	Upper Respiratory tract Infection	Infections and infestations	Placebo	8	159
other	Diarrheoa	Gastrointestinal disorders	210 mg Brodalumab	2	158
other	Diarrheoa	Gastrointestinal disorders	140 mg Brodalumab	5	158
other	Diarrheoa	Gastrointestinal disorders	Placebo	3	159
other	Headache	Nervous system disorders	210 mg Brodalumab	5	158

1 to 10 of 147Source ClinicalTrials.gov

See all 147 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	210 mg Brodalumab
Total, all-cause mortality	140 mg Brodalumab
Total, all-cause mortality	Placebo
Total, other adverse events	210 mg Brodalumab	84	158
Total, other adverse events	140 mg Brodalumab	79	158
Total, other adverse events	Placebo	71	159
Total, serious adverse events	210 mg Brodalumab	10	158
Total, serious adverse events	140 mg Brodalumab	5	158
Total, serious adverse events	Placebo	4	159

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02029495

GET https://conductscience.org/api/trials/v1/NCT02029495/events?page=2

API reference For AI assistants